ILK-IN-2

ILK-IN-2

CAT N°: 36674
Price:

From 262.00 222.70

ILK-IN-2 is an inhibitor of integrin-linked kinase (ILK; IC50 = 0.6 µM).{67063} It inhibits the phosphorylation of Akt, glycogen synthase kinase 3? (GSK3?), and myosin light-chain (MLC) in PC3 prostate and MDA-MB-231 breast cancer cells when used at concentrations ranging from 1 to 4 µM. ILK-IN-2 inhibits the proliferation of LNCaP, PC3, MDA-MB-231, MDA-MB-468, SK-BR-3, and MCF-7 cancer cells (IC50s = 1.6, 2, 1, 1.5, 1.8, and 2.5 µM, respectively), as well as induces autophagy and apoptosis in PC3 cells when used at a concentration of 2 µM. It also reduces protein levels of Y-box binding protein (YB-1), HER2, and EGFR in PC3 cells. ILK-IN-2 (25 and 50 mg/kg) reduces tumor growth in a PC3 mouse xenograft model.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-methyl-1-[4-(1-piperazinyl)phenyl]-5-[4?-(trifluoromethyl)[1,1?-biphenyl]-4-yl]-1H-pyrazole-3-propanamide
  • Correlated keywords
    • CPD22 OSUT315 OSU-T315 ILKIN IN2 ILKIN2 ILKIN1 IN1 PC MDAMB MDAMB231 MDAMB468 MB231 MB468 SKBR3 SKBR MCF7 YB1 human epidermal growth factor receptor estimated glomerular filtration rate
  • Product Overview:
    ILK-IN-2 is an inhibitor of integrin-linked kinase (ILK; IC50 = 0.6 µM).{67063} It inhibits the phosphorylation of Akt, glycogen synthase kinase 3? (GSK3?), and myosin light-chain (MLC) in PC3 prostate and MDA-MB-231 breast cancer cells when used at concentrations ranging from 1 to 4 µM. ILK-IN-2 inhibits the proliferation of LNCaP, PC3, MDA-MB-231, MDA-MB-468, SK-BR-3, and MCF-7 cancer cells (IC50s = 1.6, 2, 1, 1.5, 1.8, and 2.5 µM, respectively), as well as induces autophagy and apoptosis in PC3 cells when used at a concentration of 2 µM. It also reduces protein levels of Y-box binding protein (YB-1), HER2, and EGFR in PC3 cells. ILK-IN-2 (25 and 50 mg/kg) reduces tumor growth in a PC3 mouse xenograft model.

We also advise you